Contineum Therapeutics (CTNM) Expected to Release Earnings on Tuesday

Contineum Therapeutics (NASDAQ:CTNM) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:00 PM ET.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.16. On average, analysts expect Contineum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Contineum Therapeutics Trading Down 1.5%

Shares of NASDAQ:CTNM traded down $0.21 on Tuesday, hitting $13.65. The company had a trading volume of 6,939 shares, compared to its average volume of 289,420. The company has a market cap of $510.37 million, a PE ratio of -6.85 and a beta of 0.70. Contineum Therapeutics has a 52-week low of $5.07 and a 52-week high of $16.91. The business has a 50 day moving average of $13.53 and a 200 day moving average of $13.50.

Analysts Set New Price Targets

Several brokerages recently weighed in on CTNM. Morgan Stanley boosted their target price on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Contineum Therapeutics has an average rating of “Hold” and an average price target of $20.00.

Institutional Trading of Contineum Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp acquired a new position in shares of Contineum Therapeutics during the 4th quarter valued at about $399,000. Hudson Bay Capital Management LP purchased a new position in shares of Contineum Therapeutics during the 4th quarter worth about $296,000. Quadrature Capital Ltd acquired a new stake in shares of Contineum Therapeutics in the fourth quarter worth approximately $267,000. Schonfeld Strategic Advisors LLC grew its holdings in Contineum Therapeutics by 22.6% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 22,673 shares of the company’s stock valued at $259,000 after purchasing an additional 4,177 shares during the period. Finally, Graham Capital Management L.P. acquired a new position in Contineum Therapeutics during the fourth quarter worth approximately $195,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.